MESFER AL SHAHRANI1,2,*, PRASANNA RAJAGOPALAN1,2, MOHAMMAD ABOHASSAN1, MOHAMMAD ALSHAHRANI1, YASSER ALRAEY1, REEM M. GAHTANI1, SURESH RADHAKRISHNAN3, KHLOOD DAGREERY4
Oncology Research, Vol.29, No.3, pp. 149-157, 2021, DOI:10.32604/or.2022.03539
- 01 August 2022
Abstract Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells,
whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel
approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6-
methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical
properties of SBL-060 were identified by proton nuclear magnetic resonance (1
H-NMR), 13C-NMR, and mass
spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60
cell lines were… More >